## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.80 indicates fundamental undervaluation. Quality metrics strong (ROE 40%, ROA 14%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.59)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck**
- Source: Seacoastonline.com | 20251207T040141 | Bullish | Relevance: 100%
-  RedChip Companies congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million, highlighting the company's progress from an emerging growth story to a major acquisition. The acquisition is centered on CD388, Cidara's investigational long-acting antiviral in Phase 3 development for preventing influenza.

**2. Gabelli Funds LLC Trims Stock Position in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251208T114935 | Neutral | Relevance: 99%
- Gabelli Funds LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 6.7% in the second quarter, selling 23,500 shares and holding 326,115 shares worth $25.815 million. Other institutional investors also adjusted their positions in MRK, with several analysts providing ratings ranging from "Buy" to "Hold." The company recently announced an increased quarterly dividend of $0.85 per share, payable on January 8th, reflecting a positive financial outlook for shareholders.

**3. WINTON GROUP Ltd Makes New $3.79 Million Investment in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T141523 | Bullish | Relevance: 99%
- WINTON GROUP Ltd has made a new investment of $3.79 million in Merck & Co., Inc. (NYSE:MRK), acquiring 47,854 shares in the second quarter. Other institutional investors like DLD Asset Management, Norges Bank, and Franklin Resources also significantly increased their stakes, bringing institutional ownership to 76.07% of the company's stock. Merck recently beat earnings and revenue estimates, provided strong FY2025 guidance, and raised its quarterly dividend, while analyst sentiment remains mixed with a consensus "Hold" rating.

**4. Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK**
- Source: WBOY.com | 20251207T150846 | Neutral | Relevance: 99%
- Levi & Korsinsky LLP is urging shareholders of Merck & Co., Inc. (NYSE: MRK) to contact them by April 14, 2025, to discuss their rights regarding a class action securities lawsuit. The lawsuit alleges that Merck made misleading statements about projected Gardasil sales, leading to a significant stock drop when revised forecasts were announced. Shareholders are encouraged to seek recovery for losses incurred between February 3, 2022, and February 3, 2025.

**5. Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump**
- Source: Finviz | 20251209T164525 | Bullish | Relevance: 98%
- Merck's stock has recently experienced a rebound, partly due to encouraging clinical data for its acquired drug, Winrevair (sotatercept), which is showing promise in treating pulmonary hypertension and is expected to achieve blockbuster status. This success, along with other pipeline developments, positions Merck strongly as it prepares for the upcoming patent expiration of its key cancer drug, Keytruda, in 2028. The company's strategic acquisitions and ongoing research suggest a robust long-term outlook for investors.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- M&A activity or partnership announcements may unlock value.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $247.1B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.3 |
| Current P/E | 11.0 |
| YoY Growth | -2.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.0% to -0.7% (-5.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.70% (CS: 52) | Neutral |
| RSI_14 | 57.8 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.090x | Above |
| vs SMA200 | 1.166x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $98.93
- **Stop Loss:** $93.59 (5.4% risk)
- **Target:** $109.61 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $9,200.49
- **Portfolio %:** 9.20%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*